500087

- USFDA inspection at Cipla's subsidiary InvaGen's manufacturing facility in Central Islip, NY, USA, from July 13-17, 2026, has been classified as 'Voluntary Action Indicated (VAI)'.

- Cipla announced a group restructuring to rationalize and simplify its structure. - Aspergen Limited, India (a JV), acquired 100% stake in Aspergen Inc., USA, a step-down subsidiary. - Cipla's economic interest in Aspergen Inc., USA, remains unchanged post-restructuring.

- Cipla has scheduled meetings with analysts/institutional investors. - September 17, 2026: Jefferies India Forum Conference in Gurgaon (In person). - September 18, 2026: Kotak Healthcare Conference in Mumbai (In person).

- Cipla Ltd. allotted 5,281 fully paid-up equity shares of INR 2 each on August 26, 2026. - This allotment was made under the ESOS 2013-A Scheme and Cipla ESAR Scheme 2021. - Consequently, the company's paid-up share capital increased to INR 1,61,57,16,894, comprising 80,78,58,447 equity shares.

- USFDA conducted a cGMP inspection at Cipla's Pithampur manufacturing facility from August 17-25, 2026. - The company received seven (7) inspectional observations in Form 483. - Cipla is committed to addressing these observations comprehensively.

- Cipla Limited received NCLT approval on August 18, 2026, for the amalgamation of its wholly-owned subsidiary, Inzpera Healthsciences Limited, into Cipla. - The scheme, effective April 1, 2026, aims for operational efficiency, cost savings, and enhanced shareholder value, with no adverse impact on creditors.

- Cipla received updated ESG ratings from SES and NSE. - SES ESG rating for FY26 improved to 69.9 (Grade B) from 69.3 (Grade B) in FY25. - NSE ESG rating for FY26 declined to 67 (Aspiring) from 69 (Aspiring) in FY25, potentially due to a product recall by Cipla USA Inc. in January 2026.

- Cipla's wholly-owned subsidiary, InvaGen Pharmaceuticals, Inc., has received an Establishment Inspection Report (EIR) from the USFDA. - This indicates the closure of the Pre-Approval Inspection (PAI) at its Hauppauge, Long Island, New York, USA manufacturing facility.

- Cipla Limited allotted 7,850 fully paid-up equity shares of INR 2 each on July 31, 2026, under its ESOS 2013-A Scheme and ESAR Scheme 2021. - This allotment increased the total paid-up share capital to INR 1,61,57,06,332 (80,78,53,166 equity shares).

- Cipla received U.S. FDA approval for its Abbreviated New Drug Application (ANDA) for Generic Advair Diskus® (fluticasone propionate and salmeterol inhalation powder) in all three strengths. - The product is expected to be launched in Q2 of FY 2026-27 in the United States of America. - The U.S. market for this product is approximately $908 million.

- Company reiterates FY27 EBITDA margin guidance of 18.5% to 20%, expecting gradual improvement in coming quarters, despite some current gross margin impacts from product mix, inventory write-offs, and war-related costs. - Reaffirms target of $1 billion U.S. segment exit run rate for FY27, to be driven by new product launches including generic Ventolin, three respiratory assets (e.g., generic Advair), and a peptide product. - North America business expects sequential growth, while One India aims to sustain growth momentum across branded generic, trade generic, and consumer wellness, having achieved its highest ever Q1 revenue of INR 7,100 crores. - Capital allocation priorities include increased Capex for organic growth, R&D, biosimilars, and looking for differentiated portfolio acquisitions/in-licensing. - U.S. FDA GMP inspection at Verna, Goa facility was classified as VAI. One Form 483 observation at Invagen facility is being addressed and is not expected to delay major respiratory launches. - Net cash equivalent balance stood at INR 9,494 crores as of June 30, 2026, with debt at INR 600 crores.

- Audio recording of the earnings conference call for the quarter ended 30th June, 2026 is available on the Company's website at https://www.cipla.com/audio/15001.

- Board approved changes in Key Managerial Personnel (KMPs) and Officers authorized under Regulation 30(5), effective July 24, 2026. - The filing provides contact details for these authorized KMPs/Officers.

- Cipla Ltd. granted 5,530 stock options under ESOS 2013-A and 19,179 Employee Stock Appreciation Rights (ESARs) under ESAR 2021. - Stock options vest in 2 years, while ESARs have 3-year graded vesting. - Both have a 5-year exercise period from vesting date, with an exercise price of INR 2 per option/share.

- Board of Directors approved a change in reporting for Mr. Sanjay Joseph, Head – API Business. - He will cease to be a Senior Managerial Personnel (SMP) with effect from July 24, 2026.

- Mr. Ashish Adukia transitioned from Global Chief Financial Officer (CFO) and Key Managerial Personnel (KMP) to an internal business leadership role, effective July 23, 2026. - Mr. Dinesh Jain was appointed as Global CFO and KMP, effective July 24, 2026. Mr. Jain previously served as Head – Corporate Finance at Cipla.

- Mr. Ashish Adukia transitioned from Global CFO and KMP to an internal business leadership role, effective July 23, 2026. - Mr. Dinesh Jain, Head – Corporate Finance, has been appointed as the new Global CFO and KMP, effective July 24, 2026. Mr. Jain is a seasoned finance leader with over three decades of experience.

- Consolidated Revenue ₹7,119 Cr vs ₹6,957 Cr (▲2% YoY) - EBITDA ₹1,192 Cr vs ₹1,778 Cr (▼33% YoY) - PAT ₹789 Cr vs ₹1,298 Cr (▼39% YoY) - EBITDA Margin 16.7% vs 25.6% (▼890bps)

- Consolidated Revenue ₹7,119Cr vs ₹6,957Cr (▲2.3% YoY) - EBITDA ₹1,192Cr vs ₹1,778Cr (▼33.0% YoY) - PAT ₹789Cr vs ₹1,298Cr (▼39.2% YoY) - EBITDA Margin 16.8% vs 25.6% (▼880bps)